Search results for

The House sustained President Bush's first-ever veto of a bill to expand federal funding of embryonic stem cell research. But backers of the bill say that the politics of the measure will favor them in the end.

Investigators are still trying to determine just how much money investors lost in Bernard Madoff's alleged Ponzi scheme. Estimates run as high as $50 billion. A big question facing regulators is how they could have missed a scheme that may date back as far as 20 years.

Automaker Toyota has announced its first operating loss since 1938. The company cited a severe drop in demand for its cars, especially in the U.S., which accounts for one-third of its vehicle sales. New York Times senior correspondent Micheline Maynard offers her insight.

Treasury Secretary Geithner leaves Thursday for Great Britain, where he'll attend a meeting of the Group of 20 finance ministers and central bank governors. Those countries account for 90 percent of the global economy, and the purpose of the meeting is to come up with a coordinated plan for dealing with the international economic crisis.

Pakistan is strongly protesting a U.S. airstrike that it says killed 11 soldiers at a border post. The men were part of the Frontier Corps serving on the Pakistan-Afghanistan border. The incident is straining an already tense relationship between the countries.

The Treasury Department has proposed restrictions on debt collectors, required under the 2010 federal health law, to protect patients at nonprofit hospitals. A Supreme Court ruling that strikes down the entire law would scotch the new rules.

Evolutionary biologist Menno Schilthuizen's new book is a breezy (sometimes too breezy) account of the ways animals have adapted to city life, and the staggering impact humans have had on evolution.

The Federal Trade Commission has accused the online retailer of harboring children's data even when parents request it to be deleted, as well giving its Ring employees access to users' videos.

Amid an uproar over soaring drug prices, three GOP senators are seeking an investigation into whether the Orphan Drug Act is being manipulated to jack up the cost of medications for rare diseases.

For more than three decades, pharmaceutical companies have claimed a 50 percent tax credit for the cost of clinical trials of drugs for rare diseases. The credit is now in jeopardy.